Efficacy of buparlisib in treating breast cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Breast cancer remains a leading cause of mortality in women, with poor prognosis for advanced stages.
• The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently deregulated in breast cancer, contributing to treatment resistance.
• Targeting the PI3K pathway offers a strategy to overcome resistance to endocrine and anti-HER2 therapies.

Purpose of the Study:

• To review the preclinical and clinical development of buparlisib (BKM-120), a pan-PI3K inhibitor, in breast cancer.
• To analyze the current status, ongoing trials, and safety profile of buparlisib.
• To discuss the potential and challenges of PI3K inhibitors in breast cancer treatment.

Main Methods:

• Review of preclinical studies evaluating buparlisib's efficacy and mechanism of action.
• Analysis of clinical trial data from completed and ongoing studies of buparlisib in breast cancer patients.
• Assessment of buparlisib's safety and tolerability based on clinical trial outcomes.

Main Results:

• Buparlisib demonstrates activity as a PI3K inhibitor in preclinical and clinical settings for breast cancer.
• Ongoing trials are investigating buparlisib in various breast cancer subtypes and treatment combinations.
• The toxicity profile of buparlisib requires careful management and consideration for its clinical application.

Conclusions:

• PI3K inhibitors, including buparlisib, represent a promising therapeutic avenue for breast cancer.
• Identification of predictive biomarkers is crucial for optimizing patient selection and treatment response.
• Strategies to overcome resistance and manage toxicity are essential for the successful clinical implementation of PI3K inhibitors.